Efficacy of erythropoietin-stimulating medications in controlling anemia in CKD patients

S S I Pooja, Matta Purna Rajeena, Pitani Manisha, Rakesh Kumar Pandit, MD Zoya Alvira, Londa Eswar Naga Sai Datta Yadav*

Department of pharmacy practice, Aditya college of pharmacy, Surampalem, Andhra Pradesh, India

Refer this article

S S I Pooja, Matta Purna Rajeena, Pitani Manisha, Rakesh Kumar Pandit, MD Zoya Alvira, Londa Eswar Naga Sai Datta Yadav, 2026. Efficacy of erythropoietin-stimulating medications in controlling anemia in CKD patients. Journal of medical pharmaceutical and allied sciences, V 15, I 4, Pages 11 – 14. Doi: https://doi.org/10.55522/jmpas.V15I4.7014.

ABSTRACT

Iron deficiency, chronic inflammation, and decreased endogenous erythropoietin production are the main causes of anemia, a prevalent and crippling consequence of chronic kidney disease (CKD). To raise hemoglobin levels, lower the requirement for blood transfusions, and improve patient quality of life, erythropoietin-stimulating agents (ESAs) are now a mainstay in the treatment of CKD-associated anemia. This study evaluates the efficacy of erythropoietin-stimulating medications in treating anemia in patients with chronic kidney disease. Hemoglobin response, transfusion needs, and clinical improvement were examined as part of a thorough evaluation of CKD patients on ESA therapy. The results show that, when properly dosed and managed, ESA medication dramatically raises and keeps hemoglobin concentrations within therapeutic levels.

Keywords:

Chronic kidney disease, Anemia, Erythropoietin-stimulating hemoglobin, Erythropoietin-stimulating agents, Chronic kidney disease, Renal anemia, ESA therapy.

Full Text Article